

BenevolentAI

BenevevolentAI is a global pioneer and leader in AI-augmented drug discovery. We serve patients by leveraging our proprietary and validated Benevolent Platform that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, Benevolent is well-positioned to identify and accelerate novel drug discoveries.
Founding Year
2013
Headquarters
,
United Kingdom
Sector(s)
No items found.
Funding State
Pre-Seed
Seed
Series A
Series B+
Exited
Total Funding Amount
$292.00M
Funds that Investested
No items found.
Investors that Investested
No items found.
Round-focused Sheets
Geography-focused Sheets
Sector-focused Sheets